BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CEO Sells $262,304.02 in Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CEO Herm Cukier sold 38,461 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.82, for a total value of $262,304.02. Following the sale, the chief executive officer now owns 74,842 shares in the company, valued at $510,422.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ:BDSI traded down $0.06 during mid-day trading on Wednesday, hitting $6.70. 1,116,894 shares of the stock traded hands, compared to its average volume of 974,221. The stock has a market capitalization of $605.16 million, a price-to-earnings ratio of -9.18 and a beta of 0.49. BioDelivery Sciences International, Inc. has a 52 week low of $2.80 and a 52 week high of $7.01. The firm’s 50 day moving average is $5.91 and its two-hundred day moving average is $4.74. The company has a quick ratio of 2.02, a current ratio of 2.25 and a debt-to-equity ratio of 0.86.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.34. The company had revenue of $30.31 million for the quarter, compared to analyst estimates of $28.86 million. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. As a group, research analysts predict that BioDelivery Sciences International, Inc. will post 0.02 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of BioDelivery Sciences International by 277.2% during the second quarter. BlackRock Inc. now owns 5,498,457 shares of the specialty pharmaceutical company’s stock valued at $25,568,000 after buying an additional 4,040,621 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of BioDelivery Sciences International by 30.5% in the second quarter. Vanguard Group Inc. now owns 3,395,428 shares of the specialty pharmaceutical company’s stock valued at $15,788,000 after purchasing an additional 793,179 shares during the period. Stonepine Capital Management LLC boosted its holdings in shares of BioDelivery Sciences International by 79.6% in the second quarter. Stonepine Capital Management LLC now owns 2,764,475 shares of the specialty pharmaceutical company’s stock valued at $12,855,000 after purchasing an additional 1,225,038 shares during the period. Emerald Advisers LLC boosted its holdings in shares of BioDelivery Sciences International by 11.4% in the third quarter. Emerald Advisers LLC now owns 2,084,685 shares of the specialty pharmaceutical company’s stock valued at $8,777,000 after purchasing an additional 212,553 shares during the period. Finally, Emerald Mutual Fund Advisers Trust grew its stake in BioDelivery Sciences International by 13.8% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,944,531 shares of the specialty pharmaceutical company’s stock worth $8,186,000 after purchasing an additional 236,254 shares in the last quarter. 69.44% of the stock is currently owned by hedge funds and other institutional investors.

BDSI has been the subject of a number of recent research reports. ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Tuesday. Janney Montgomery Scott reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Wednesday, November 13th. TheStreet upgraded BioDelivery Sciences International from a “d” rating to a “c” rating in a report on Friday, November 22nd. William Blair restated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. Finally, LADENBURG THALM/SH SH raised their price target on BioDelivery Sciences International from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $6.50.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: Backdoor Roth IRA

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.